238 related articles for article (PubMed ID: 19930847)
21. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.
Scorpio A; Lindholm-Levy P; Heifets L; Gilman R; Siddiqi S; Cynamon M; Zhang Y
Antimicrob Agents Chemother; 1997 Mar; 41(3):540-3. PubMed ID: 9055989
[TBL] [Abstract][Full Text] [Related]
22. Association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
Aono A; Chikamatsu K; Yamada H; Kato T; Mitarai S
Antimicrob Agents Chemother; 2014 Aug; 58(8):4928-30. PubMed ID: 24867972
[TBL] [Abstract][Full Text] [Related]
23. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis.
Hirano K; Takahashi M; Kazumi Y; Fukasawa Y; Abe C
Tuber Lung Dis; 1997; 78(2):117-22. PubMed ID: 9692180
[TBL] [Abstract][Full Text] [Related]
24. [Studies on pncA gene mutations in M. tuberculosis isolates].
Wu X; Zhang J; Zhong M
Zhonghua Jie He He Hu Xi Za Zhi; 2000 Jan; 23(1):40-2. PubMed ID: 11778181
[TBL] [Abstract][Full Text] [Related]
25. New mutations in pncA of in vitro selected pyrazinamide-resistant strains of Mycobacterium tuberculosis.
Bamaga M; Zhang H; Wright DJ
Microb Drug Resist; 2001; 7(3):223-8. PubMed ID: 11759083
[TBL] [Abstract][Full Text] [Related]
26. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.
Mestdagh M; Fonteyne PA; Realini L; Rossau R; Jannes G; Mijs W; De Smet KA; Portaels F; Van den Eeckhout E
Antimicrob Agents Chemother; 1999 Sep; 43(9):2317-9. PubMed ID: 10471589
[TBL] [Abstract][Full Text] [Related]
27. Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico.
Cuevas-Córdoba B; Xochihua-González SO; Cuellar A; Fuentes-Domínguez J; Zenteno-Cuevas R
Infect Genet Evol; 2013 Oct; 19():330-4. PubMed ID: 23321280
[TBL] [Abstract][Full Text] [Related]
28. Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance.
Zimic M; Sheen P; Quiliano M; Gutierrez A; Gilman RH
Infect Genet Evol; 2010 Mar; 10(2):346-9. PubMed ID: 19963078
[TBL] [Abstract][Full Text] [Related]
29. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea.
Lee KW; Lee JM; Jung KS
J Korean Med Sci; 2001 Oct; 16(5):537-43. PubMed ID: 11641519
[TBL] [Abstract][Full Text] [Related]
30. Estimation of pyrazinamidase activity using a cell-free
Rueda D; Bernard C; Gandy L; Capton E; Boudjelloul R; Brossier F; Veziris N; Zimic M; Sougakoff W
Int J Mycobacteriol; 2018; 7(1):16-25. PubMed ID: 29516881
[TBL] [Abstract][Full Text] [Related]
31. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.
Kim HJ; Kwak HK; Lee J; Yun YJ; Lee JS; Lee MS; Min SY; Park SK; Kang HS; Maeng YH; Kim SY; Kim SY; Kook YH; Kim YR; Lee KH
Int J Tuberc Lung Dis; 2012 Jan; 16(1):98-103. PubMed ID: 22236853
[TBL] [Abstract][Full Text] [Related]
32. Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India.
Muthaiah M; Jagadeesan S; Ayalusamy N; Sreenivasan M; Prabhu SS; Muthuraj U; Senthilkumar K; Veerappan S
Int J Mol Sci; 2010 Jul; 11(7):2670-80. PubMed ID: 20717529
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
Pang Y; Zhu D; Zheng H; Shen J; Hu Y; Liu J; Zhao Y
BMC Infect Dis; 2017 Nov; 17(1):711. PubMed ID: 29110640
[TBL] [Abstract][Full Text] [Related]
34. Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method.
Zhou M; Geng X; Chen J; Wang X; Wang D; Deng J; Zhang Z; Wang W; Zhang XE; Wei H
PLoS One; 2011; 6(11):e27654. PubMed ID: 22102918
[TBL] [Abstract][Full Text] [Related]
35. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.
Miotto P; Cabibbe AM; Feuerriegel S; Casali N; Drobniewski F; Rodionova Y; Bakonyte D; Stakenas P; Pimkina E; Augustynowicz-Kopeć E; Degano M; Ambrosi A; Hoffner S; Mansjö M; Werngren J; Rüsch-Gerdes S; Niemann S; Cirillo DM
mBio; 2014 Oct; 5(5):e01819-14. PubMed ID: 25336456
[TBL] [Abstract][Full Text] [Related]
36. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.
Zimic M; Fuentes P; Gilman RH; Gutiérrez AH; Kirwan D; Sheen P
Tuberculosis (Edinb); 2012 Jan; 92(1):84-91. PubMed ID: 22004792
[TBL] [Abstract][Full Text] [Related]
37. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis.
Morlock GP; Crawford JT; Butler WR; Brim SE; Sikes D; Mazurek GH; Woodley CL; Cooksey RC
Antimicrob Agents Chemother; 2000 Sep; 44(9):2291-5. PubMed ID: 10952570
[TBL] [Abstract][Full Text] [Related]
38. Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.
Whitfield MG; Warren RM; Streicher EM; Sampson SL; Sirgel FA; van Helden PD; Mercante A; Willby M; Hughes K; Birkness K; Morlock G; van Rie A; Posey JE
J Clin Microbiol; 2015 Nov; 53(11):3633-5. PubMed ID: 26292310
[TBL] [Abstract][Full Text] [Related]
39. Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm.
Simons SO; van der Laan T; Mulder A; van Ingen J; Rigouts L; Dekhuijzen PN; Boeree MJ; van Soolingen D
Clin Microbiol Infect; 2014 Oct; 20(10):1015-20. PubMed ID: 24890253
[TBL] [Abstract][Full Text] [Related]
40. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing.
Shenai S; Rodrigues C; Sadani M; Sukhadia N; Mehta A
Indian J Tuberc; 2009 Apr; 56(2):82-90. PubMed ID: 19810590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
